ENTBF (Entheon Biomedical) Debt-to-Equity: 0.00 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Entheon Biomedical Debt-to-Equity?

Entheon Biomedical ENTBF Debt-to-Equity is 0.00 as of May. 2026. Among 965 Biotechnology companies, Entheon Biomedical ranks worse than 103626.84% on this metric.

Entheon Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2026 was $0.00 Mil. Entheon Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2026 was $0.00 Mil. Entheon Biomedical's Total Stockholders Equity for the quarter that ended in May. 2026 was $0.35 Mil. Entheon Biomedical's debt to equity for the quarter that ended in May. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Entheon Biomedical's Debt-to-Equity or its related term are showing as below:

During the past 9 years, the highest Debt-to-Equity Ratio of Entheon Biomedical was 0.06. The lowest was 0.06. And the median was 0.06.

ENTBF's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Entheon Biomedical  (OTCPK:ENTBF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Entheon Biomedical Debt-to-Equity Related Terms

Entheon Biomedical Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Entheon Biomedical's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entheon Biomedical Debt-to-Equity Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23 Nov24 Nov25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entheon Biomedical Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ENTBF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison

For the Biotechnology subindustry, Entheon Biomedical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entheon Biomedical Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Debt-to-Equity falls into.


Entheon Biomedical Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Entheon Biomedical's Debt to Equity Ratio for the fiscal year that ended in Nov. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0.231
=0.00

Entheon Biomedical's Debt to Equity Ratio for the quarter that ended in May. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 0.35
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Entheon Biomedical (ENTBF) has a Debt-to-Equity of 0.00 as of May. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Entheon Biomedical and its competitors. Over the past decade, Entheon Biomedical's Debt-to-Equity has ranged from 0.06 to 0.06. According to the industry distribution chart, Entheon Biomedical ranks #999999 out of 965 companies in the Biotechnology industry.
Is Entheon Biomedical's Debt-to-Equity too high?
Entheon Biomedical's current Debt-to-Equity is 0.00. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.06. Based on the distribution chart, Entheon Biomedical ranks #999999 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Entheon Biomedical's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entheon Biomedical ranks #999999 out of 965 companies for Debt-to-Equity. This places Entheon Biomedical in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Historically, Entheon Biomedical's own Debt-to-Equity has ranged from 0.06 to 0.06 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Entheon Biomedical and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entheon Biomedical's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entheon Biomedical stock overvalued right now?
Entheon Biomedical (ENTBF) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Entheon Biomedical (ENTBF), the current Debt-to-Equity is 0.00 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entheon Biomedical Business Description

Other Exchanges 1XU:GermanyENBI.X:Canada
Address 999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company focused on treating addiction and substance use disorders.